PIK3CA and neoplasm: However, PIK3CA or RAS mutations were not significantly associated with progression (p = 0.129, p = 0.694) or disease-specific survival (p = 0.205, p = 0.447) in the entire cohort, nor in different tumor stage and grade subgroups.